Sclerostin, a
protein expressed by osteocytes, is a negative regulator of bone formation. The aim of the study was to investigate the relationship between
parathyroid hormone (PTH) and markers of bone metabolism and changes of sclerostin concentrations before and
after treatment of
hyperthyroidism. Patients and Methods. The study involved 33 patients (26 women), age (mean ± SD) 48 ± 15 years, with
hyperthyroidism. Serum sclerostin, PTH,
calcium, and bone markers [
osteocalcin (OC) and
collagen type I cross-linked
C-telopeptide I (CTX)] were measured at diagnosis of
hyperthyroidism and
after treatment with
thiamazole. Results.
After treatment of
hyperthyroidism a significant decrease in free T3 (FT3) and free T4 (FT4) concentrations was accompanied by marked decrease of serum sclerostin (from 43.7 ± 29.3 to 28.1 ± 18.4 pmol/L; p < 0.001), OC (from 35.6 ± 22.0 to 27.0 ± 14.3 ng/mL; p < 0.001), and CTX (from 0.49 ± 0.35 to 0.35 ± 0.23 ng/dL; p < 0.005), accompanied by an increase of PTH (from 29.3 ± 14.9 to 39.8 ± 19.8; p < 0.001). During
hyperthyroidism there was a positive correlation between sclerostin and CTX (r s = 0.41, p < 0.05) and between OC and
thyroid hormones (with FT3 r s = 0.42, with FT4 r s = 0.45, p < 0.05). Conclusions. Successful treatment of
hyperthyroidism results in a significant decrease in serum sclerostin and bone markers concentrations, accompanied by an increase of PTH.